PXL770: adverse events and evidence limits
An oral PXL770 trial in nonalcoholic fatty liver disease, assessed at week 12, reported diarrhea as the most frequent treatment-emergent event. Treatment-emergent adverse events overall occurred in all arms, including placebo. [1]
The abstract, rather than complete safety tables, was read. Dose groups were not pooled; another preparation’s safety is not established. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | Patients with nonalcoholic fatty liver disease, oral PXL770, assessed at week 12 | The most frequent treatment-emergent event in the abstract; no percentage given, and complete safety tables were not read | [1] |
| Treatment-emergent adverse events overall | The same patients, all trial arms | Occurred in all arms, including placebo; dose groups were not pooled | [1] |
References
- Kenneth Cusi et al. (2021). Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study https://doi.org/10.1016/S2468-1253(21)00300-9.